Request samples
of Stiolto Respimat

STIOLTO Sample Box

Get your patients started, request samples of STIOLTO RESPIMAT online.

Request samples

Over 2,000,000 more prescriptions for medicines in RESPIMAT have been written than for medicines in Ellipta®1*

*Based on IMS data collected from October 2013 through September 2017.

ELLIPTA is a registered trademark of the GSK group of companies.

Prescribe knowing there’s coverage and savings
to help your patients start and stay on therapy

STIOLTO RESPIMAT Savings Card

Copays as low as $0

Patients may also be eligible to pay as little as $0 with the STIOLTO RESPIMAT Savings Card. Call 1‑877‑498‑7429 with any questions.

Flag your patients for STIOLTO RESPIMAT knowing there’s Medicare coverage:

  • STIOLTO RESPIMAT costs ~31% less than Trelegy Ellipta§
  • As a reminder, typically dual-eligible patients have no copay under Medicare Part D 

Please see Terms and Conditions below. Medicare/Medicaid/cash-paying patients excluded from Savings Card enrollment. Patients requiring further assistance can access benefits through the patient assistance program, BI Cares, at BIPatientAssistance.com.

§Trelegy Ellipta is a trademark of the GSK group of companies.

Source: Fingertip Formulary, health plan or state listed above, and/or data on file, Boehringer Ingelheim Pharmaceuticals, Inc. as of 08/01/2018.

Placement on formulary does not establish clinical comparability of products, including safety and efficacy, and is not a guarantee of full or partial coverage and/or payment. Contact health plan, state, or www.medicare.gov for most current information, as it may change without notice. This is not intended to be an exhaustive list of all plans in your area. Boehringer Ingelheim Pharmaceuticals, Inc. does not sponsor or endorse any particular plan. 

Support Tools & Resources
for you and your patients

Respi Points

Help your patients stick to their treatment with RespiPointsTM

This free, exclusive rewards program is a great way for your COPD patients on STIOLTO RESPIMAT to get the most out of their treatment.

Recommend today

Savings program
Terms and conditions

To the Patient: Eligible commercially insured patients 18 years or older may pay as little as $0/month with a maximum savings up to $380/monthly prescription. Card valid for 12 consecutive months from activation date. Eligible patients may re-enroll for additional 12 consecutive-month periods by reactivating expired card, benefits not to exceed program expiration on 12/31/2019. If you live in Massachusetts, card expires on the earlier of June 30, 2019, or date AB-rated generic equivalent is available. One card per patient, not transferable, and cannot be combined with any other offer. Card not accepted in Veteran’s Affairs pharmacies. Program not health insurance. You must present this card to the pharmacist with your STIOLTO RESPIMAT prescription to participate. Only valid for commercially insured patients in the 50 United States, territories, DC, and Puerto Rico. Not eligible if prescriptions are paid for in part/full by state or federally funded program(s), like Medicare Part D, Medicaid, Veteran’s Affairs, Dept. of Def., or TRICARE and where prohibited by law. Offer may change at any time, without notice.

IMPORTANT SAFETY INFORMATION and INDICATION for STIOLTO RESPIMAT

WARNING: ASTHMA‑RELATED DEATH

Long‑acting beta2‑adrenergic agonists (LABA) such as olodaterol, one of the active ingredients in STIOLTO RESPIMAT, increase the risk of asthma‑related death. Data from a large, placebo‑controlled US study that compared the safety of another long‑acting beta2‑adrenergic agonist (salmeterol) with placebo added to usual asthma therapy showed an increase in asthma‑related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of all LABA, including olodaterol, one of the active ingredients in STIOLTO RESPIMAT. The safety and efficacy of STIOLTO RESPIMAT in patients with asthma have not been established. STIOLTO RESPIMAT is not indicated for the treatment of asthma.

CONTRAINDICATION

All LABA are contraindicated in patients with asthma without use of a long‑term asthma control medication. STIOLTO is contraindicated in patients with hypersensitivity to tiotropium, ipratropium (atropine derivatives), olodaterol, or any component of this product.

In clinical trials and postmarketing experience with tiotropium, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported. Hypersensitivity reactions were also reported in clinical trials with STIOLTO.

WARNINGS AND PRECAUTIONS

STIOLTO should not be initiated in patients with acutely deteriorating COPD, which may be a life‑threatening condition, or used as rescue therapy for acute symptoms. Acute symptoms should be treated with an inhaled short‑acting beta2‑agonist. Patients who have been taking inhaled, short‑acting beta2‑agonists on a regular basis should discontinue the regular use of these drugs and use them only for acute respiratory symptoms.

STIOLTO should not be used more often or at higher doses than recommended, or in conjunction with other LABA as an overdose may result.

Immediate hypersensitivity reactions, including urticaria, angioedema, rash, bronchospasm, anaphylaxis, or itching may occur after administration of STIOLTO. If such a reaction occurs, discontinue therapy with STIOLTO and consider alternative treatments. Patients with a history of hypersensitivity reactions to atropine or its derivatives should be closely monitored for similar hypersensitivity reactions to STIOLTO.

If paradoxical bronchospasm occurs, STIOLTO should be discontinued immediately.

STIOLTO can produce a clinically significant cardiovascular effect in some patients, as measured by increases in pulse rate, systolic or diastolic blood pressure, and/or symptoms. If such effects occur, STIOLTO may need to be discontinued.

Use caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, in patients with known or suspected prolongation of the QT interval, and in patients who are unusually responsive to sympathomimetic amines.

Use with caution in patients with narrow‑angle glaucoma. Instruct patients to contact a physician immediately if signs or symptoms of acute narrow‑angle glaucoma develop (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema).

Use with caution in patients with urinary retention, which can be associated with symptoms like difficulty passing urine and painful urination in patients with prostatic hyperplasia or bladder‑neck obstruction. Instruct patients to consult a physician immediately should any of these signs or symptoms develop.

Patients with moderate to severe renal impairment (creatinine clearance of <60 mL/min) treated with STIOLTO should be monitored closely for anticholinergic side effects.

Be alert to hypokalemia, which has the potential to produce adverse cardiovascular effects. Be alert to hyperglycemia.

ADVERSE REACTIONS

The most common adverse reactions with STIOLTO (>3% incidence and higher than any of the comparators — tiotropium and/or olodaterol) were: nasopharyngitis, 12.4% (11.7%/12.6%), cough, 3.9% (4.4%/3.0%), and back pain, 3.6% (1.8%/3.4%).

DRUG INTERACTIONS

  • Use caution if administering adrenergic drugs because sympathetic effects of olodaterol may be potentiated.
  • Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of olodaterol.
  • Beta agonists, such as olodaterol, can acutely worsen the ECG changes and/or hypokalemia that may result from administration of non‑potassium sparing diuretics. The action of adrenergic agents on the cardiovascular system may be potentiated by monoamine oxidase inhibitors or tricyclic antidepressants or other drugs known to prolong the QTc interval. Therefore beta‑agonists should be used with extreme caution in patients being treated with these drugs. Drugs that prolong the QTc interval may be associated with an increased risk of ventricular arrhythmias.
  • Beta‑blockers should be used with caution as they can inhibit the therapeutic effect of beta agonists which may produce severe bronchospasms in patients with COPD. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta‑blockers in patients with COPD. In this setting, cardio selective beta‑blockers could be considered, although they should be administered with caution.
  • Avoid co‑administration of STIOLTO with other anticholinergic‑containing drugs as this may lead to an increase in anticholinergic adverse effects.

STIOLTO is for oral inhalation only. The STIOLTO cartridge is only intended for use with the STIOLTO RESPIMAT inhaler.

Inform patients not to spray STIOLTO into the eyes.

INDICATION for STIOLTO RESPIMAT

Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray is a combination of tiotropium, an anticholinergic, and olodaterol, a long‑acting beta2‑adrenergic agonist (LABA), indicated for the long‑term, once‑daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Important Limitations of Use

STIOLTO is NOT indicated to treat acute deterioration of COPD and is not indicated to treat asthma.

CL-STO-0043 6.23.2016

Please see full Prescribing Information, including boxed WARNING, Medication Guide, and Instructions for Use.

Reference: 1. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.